Amino Collective
Venture capitalBerlin · Pre-Seed–Series A · 8 people tracked
Investment thesis
Amino Collective invests in founders who dare to venture into the unknown, valuing originality and boldness over conventional approaches. The firm's ethos centers on backing 'free and radical' entrepreneurs who pursue differentiated paths rather than incremental ideas.
Source: firm website, verified Aug 3, 2026.
Team · 8 people
from the firm's website & public directoriesWhat they invest in
from 1 of 32 portfolio companiesEnterprise Software ×1Fintech ×1SaaS ×1
HQs:United States×1
Investments · 32 tracked
founders shown can be your intro pathContract Research Organization for drug discovery using machine learning to accelerate compound optimization.
Combines diagnostics, clinical expertise, and causal AI to help consumers understand their health and guide behavioral change.
Hypothesis-free approach for drug discovery targeting deadliest cancers using genetic computational systems and polymathic AI.
AI-driven data management and productivity platform to run predictable clinical trials and identify therapeutic benefits early.
Delivers end-to-end clinical trials through full-service platform integrating study design, recruitment, management, and data.
AI assistant enabling clinicians to focus on patient care instead of administrative tasks.
Transforms drug discovery with predictive validity at scale.
Provides governed foundation for enterprise AI where agents, teams, and systems share context and coordinate work.
AI for personalized medicine and drug development through image-based quantification of single-cell phenotypes.
Fundrbird provides software solutions for GP (general partner) firms to build and scale their fund management operations.
Enterprise SoftwareFintechSaaS
Unlocks gene therapy potential through novel DNA modality enabling safe, effective, and flexible in vivo correction of genetic diseases.
Enables precision medicine through platform for easy genomic data orchestration and workflow creation.
Single API integrating 500+ devices including wearables and at-home kits to consolidate health data in hours instead of months.
Platform enabling healthcare providers to make better treatment decisions through compliant, easy, and affordable liquid biopsy tests.
Reprogramming viral vectors for therapeutic applications.
Integrates machine learning, metabolomics, and robotics with anthropological, biological, and chemical data from medicinal plants.
Develops life-saving cancer treatments with mRNA designed by combining latest research with synthetic biology and machine learning.
Fundamental new way of analyzing proteins through nanopore sensing for biomedicine, healthcare, and industrial applications.
Drug discovery engine using precision fermentation to find and scale new-to-nature medicines for pain, addiction, and depression.
Solves protein design for biologists using prediction algorithms and AI design suggestions for optimized thermostability and activity.
Helps life science companies navigate regulatory requirements to bring products to market faster and more affordably.
Unlocks RNA therapeutics by moving mRNA manufacturing to living cells for 10x better, scalable, cost-effective production.
Uses AI model of patient biology to predict clinical trial success, fast-tracking cleared drugs to market in 2-3 years.
New York, US
Michael Retchin(Executive Officer, Director)
Connects patients, researchers, entrepreneurs, and funders through world's first IP-NFT marketplace for fast collaboration and knowledge-sharing.
Agentic AI system that automates scientific research and development workflows.
Builds robotic labs that physically test AI drug-design models, closing the gap between computational candidates and validated compounds.
Redefines gene expression for drug development through foundational redesign of synthetic DNA instructions powered by AI.
Next-generation care enabled through online consultation with productivity tools and system-wide integration for faster patient care.
Closes the loop in the textile industry by turning blended textile waste into virgin-grade raw materials using enzymatic processes.
Maps druggable transcriptome to create discovery platform powering first-in-class small molecule programs for undruggable proteins.
Revolutionizes drug development through first multi-modal virtual patient models.
Extends healthy life-expectancy for women through digital therapeutics for menopause combining data, clinical practice, and behavior.
Frequently asked questions
- What stage does Amino Collective invest at?
- Amino Collective invests at the Pre-Seed, Seed, Series A stages.
- What is Amino Collective's typical check size?
- Amino Collective typically writes checks of $216K – $1.6M.
- What sectors does Amino Collective focus on?
- Amino Collective focuses on Biotech, Digital Health, Healthtech.
- Where is Amino Collective located?
- Amino Collective is headquartered in Berlin, DE.
Images
Co-investors · 30
Founders Fund is a venture capital firm that invests in companies building transformative technologies across defense, space, data analytics, and other frontier sectors.
Pioneer Fund is a venture capital firm investing in the top Y Combinator startups.
Headline is a venture capital firm that invests in early-stage consumer internet and mobile companies across global markets.
Creandum is a venture capital firm that backs early-stage technology companies before their potential becomes obvious.
Entrepreneur First (EF) is a talent investor that helps individuals build and launch startups, providing support such as US visa guidance, office space, fundraising preparation, and investor introductions culminating in a San Francisco Demo Day.
Antler is an early-stage venture capital firm operating across major technology ecosystems worldwide, backing entrepreneurs from company formation onward and supporting a large global portfolio of startups, including many AI companies.
Cherry Ventures is an early-stage European venture capital firm that backs founders across a range of industries including AI, energy, gaming, and space technology.
Lakestar is a European investment firm founded by Dr. Klaus Hommels in 2012, managing over $6 billion across institutional venture capital funds and personal investments, focused on backing sector-defining technology companies and supporting Europe's technological sovereignty.
Acequia Capital is an early-stage investment platform supporting technical founders and product teams building global technology businesses.
Heartcore Capital is an early-stage venture firm backing European founders from inception through Series A, with a dedicated practice investing in Web3 protocols.
Freigeist Capital is an early-stage technology investor that partners with founders at the Seed and pre-Series A stages, providing capital alongside hands-on operational support.
LocalGlobe is part of a multi-generational Phoenix Court platform that backs companies from pre-seed through public markets, founded by the Klein family who are considered founders of European seed investing with multi-decade relationships across the European tech ecosystem. The fund operates from a physical founder village at Phoenix Court in London and focuses on backing unconventional entrepreneurs in specific geographic neighbourhoods, having been among the earliest institutional backers of European outliers like Wise, Zoopla, and Citymapper.
▶18 more co-investors
Dawn Capital LLPHummingbird VenturesPresight CapitalFifty YearsTMV LogisticsMolten VenturesBand of AngelsAlbionVCAvalanche VCBlueYard CapitalN26Air Street CapitalTalis Capital42CAPCerulean VenturesCambridge Angels groupFaberPalo Santo VC
Firms observed investing alongside Amino Collective, from public investor directories. Shared companies are the overlap with Amino Collective's recorded portfolio.
Similar investors
Lux Capital's portfolio page showcasing select companies across science and technology sectors including AI infrastructure, aerospace, biotech, and productivity software.
Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
Cancer Focus Fund is an oncology-focused investment fund established in partnership with The University of Texas MD Anderson Cancer Center to fund and support promising cancer therapies.
Debiopharm Innovation Fund is the strategic corporate venture fund of Debiopharm, investing in and advising health tech startups that are transforming pharmaceutical R&D and cancer care.















